1. Home
  2. QNCX vs MSD Comparison

QNCX vs MSD Comparison

Compare QNCX & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$3.06

Market Cap

167.0M

Sector

Health Care

ML Signal

HOLD

Logo Morgan Stanley Emerging Markets Debt Fund Inc.

MSD

Morgan Stanley Emerging Markets Debt Fund Inc.

HOLD

Current Price

$7.58

Market Cap

151.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNCX
MSD
Founded
2012
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
167.0M
151.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
QNCX
MSD
Price
$3.06
$7.58
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$7.67
N/A
AVG Volume (30 Days)
979.1K
70.2K
Earning Date
11-12-2025
01-01-0001
Dividend Yield
N/A
11.26%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$6.11
52 Week High
$4.55
$7.46

Technical Indicators

Market Signals
Indicator
QNCX
MSD
Relative Strength Index (RSI) 47.31 65.51
Support Level $2.85 $7.44
Resistance Level $3.72 $7.52
Average True Range (ATR) 0.31 0.06
MACD 0.01 0.01
Stochastic Oscillator 41.38 94.23

Price Performance

Historical Comparison
QNCX
MSD

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

Share on Social Networks: